IGF1R facilitates epithelial-mesenchymal transition and cancer stem cell properties in neuroblastoma via the STAT3/AKT axis

References

• Valter K, Zhivotovsky B, Gogvadze V. Cell death-based treatment of neuroblastoma. Cell Death Dis. 2018;9:113. doi:10.1038/s41419-018-1111-y29371588
   PubMed Web of Science ®Google Scholar
• Mlakar V, Jurkovic Mlakar S, Lopez G, Maris JM, Ansari M, Gumy-Pause F. 11q deletion in neuroblastoma: a review of biological and clinical implications. Mol Cancer. 2017;16:114. doi:10.1186/s12943-017-0686-828662712
   PubMed Web of Science ®Google Scholar
• Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18:43–73. 23237552
   PubMedGoogle Scholar
• Ahmed AA, Zhang L, Reddivalla N, Hetherington M. Neuroblastoma in children: update on clinicopathologic and genetic prognostic factors. Pediatr Hematol Oncol. 2017;34:165–185. doi:10.1080/08880018.2017.133037528662353
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang H, Jiang X, Qian C, Liu Z, Luo D. Factors involved in cancer metastasis: a better understanding to “seed and soil” hypothesis. Mol Cancer. 2017;16:176. doi:10.1186/s12943-017-0742-429197379
   PubMed Web of Science ®Google Scholar
• Huang R, Rofstad EK. Cancer stem cells (CSCs), cervical CSCs and targeted therapies. Oncotarget. 2017;8:35351–35367. doi:10.18632/oncotarget.1016927343550
   PubMedGoogle Scholar
• Boumahdi S, Driessens G, Lapouge G, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014;511:246–250. doi:10.1038/nature1330524909994
   PubMed Web of Science ®Google Scholar
• Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124–1134. doi:10.1038/nm.440928985214
   PubMed Web of Science ®Google Scholar
• Alvarado AG, Thiagarajan PS, Mulkearns-Hubert EE, et al. Glioblastoma cancer stem cells evade innate immune suppression of self-renewal through reduced TLR4 expression. Cell Stem Cell. 2017;20:450–461 e454. doi:10.1016/j.stem.2016.12.00128089910
   PubMed Web of Science ®Google Scholar
• Li S, Li Q. Cancer stem cells and tumor metastasis (Review). Int J Oncol. 2014;44:1806–1812. doi:10.3892/ijo.2014.236224691919
   PubMed Web of Science ®Google Scholar
• Chang JC. Cancer stem cells: role in tumor growth, recurrence, metastasis, and treatment resistance. Medicine (Baltimore). 2016;95:S20–S25. doi:10.1097/MD.000000000000476627611935
   PubMed Web of Science ®Google Scholar
• Garner EF, Beierle EA. Cancer stem cells and their interaction with the tumor microenvironment in neuroblastoma. Cancers (Basel). 2015;8:5. doi:10.3390/cancers8010005
   PubMed Web of Science ®Google Scholar
• Chen T, You Y, Jiang H, Wang ZZ. Epithelial-mesenchymal transition (EMT): a biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol. 2017;232:3261–3272. doi:10.1002/jcp.2579728079253
   PubMed Web of Science ®Google Scholar
• Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013;27:2192–2206. doi:10.1101/gad.225334.11324142872
   PubMed Web of Science ®Google Scholar
• Cao H, Xu E, Liu H, Wan L, Lai M. Epithelial-mesenchymal transition in colorectal cancer metastasis: a system review. Pathol Res Pract. 2015;211:557–569. doi:10.1016/j.prp.2015.05.01026092594
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou BP. Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer. 2011;30:603–611. doi:10.5732/cjc.011.1022621880181
   PubMedGoogle Scholar
• Beuran M, Negoi I, Paun S, et al. The epithelial to mesenchymal transition in pancreatic cancer: a systematic review. Pancreatology. 2015;15:217–225. doi:10.1016/j.pan.2015.02.01125794655
   PubMed Web of Science ®Google Scholar
• Skovierova H, Okajcekova T, Strnadel J, Vidomanova E, Halasova E. Molecular regulation of epithelial-to-mesenchymal transition in tumorigenesis (Review). Int J Mol Med. 2018;41:1187–1200. doi:10.3892/ijmm.2017.332029286071
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166:21–45. doi:10.1016/j.cell.2016.06.02827368099
   PubMed Web of Science ®Google Scholar
• Tian X, Zhou D, Chen L, et al. Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway. Cell Death Dis. 2018;9:54. doi:10.1038/s41419-018-1111-y29352113
   PubMed Web of Science ®Google Scholar
• Wang M, Zhao J, Zhang L, et al. Role of tumor microenvironment in tumorigenesis. J Cancer. 2017;8:761–773. doi:10.7150/jca.1764828382138
   PubMed Web of Science ®Google Scholar
• Zhang X, Nie D, Chakrabarty S. Growth factors in tumor microenvironment. Front Biosci (Landmark Ed). 2010;15:151–165. 20036812
   PubMed Web of Science ®Google Scholar
• Chen HX, Sharon E. IGF-1R as an anti-cancer target–trials and tribulations. Chin J Cancer. 2013;32:242–252. doi:10.5732/cjc.012.1026323601239
   PubMed Web of Science ®Google Scholar
• Ho WL, Chou CH, Jeng YM, et al. GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma. Oncotarget. 2014;5:12247–12259. doi:10.18632/oncotarget.262725362349
   PubMedGoogle Scholar
• Cox OT, O’Shea S, Tresse E, Bustamante-Garrido M, Kiran-Deevi R, O’Connor R. IGF-1 receptor and adhesion signaling: an important axis in determining cancer cell phenotype and therapy resistance. Front Endocrinol (Lausanne). 2015;6:106. doi:10.3389/fendo.2015.0010626191041
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, et al. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci Rep. 2013;3:2560. doi:10.1038/srep0256023994953
   PubMed Web of Science ®Google Scholar
• Li H, Batth IS, Qu X, et al. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Mol Cancer. 2017;16:6. doi:10.1186/s12943-016-0576-528137302
   PubMed Web of Science ®Google Scholar
• Xu L, Zhou R, Yuan L, et al. IGF1/IGF1R/STAT3 signaling-inducible IFITM2 promotes gastric cancer growth and metastasis. Cancer Lett. 2017;393:76–85. doi:10.1016/j.canlet.2017.02.01428223169
   PubMed Web of Science ®Google Scholar
• Peake BF, Eze SM, Yang L, Castellino RC, Nahta R. Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling. Oncotarget. 2017;8:94393–94406. doi:10.18632/oncotarget.2176529212236
   PubMedGoogle Scholar
• Zhao C, Wang Q, Wang B, et al. IGF-1 induces the epithelial-mesenchymal transition via Stat5 in hepatocellular carcinoma. Oncotarget. 2017;8:111922–111930. doi:10.18632/oncotarget.2295229340101
   PubMedGoogle Scholar
• Shan J, Shen J, Liu L, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 2012;56:1004–1014. doi:10.1002/hep.2574522473773
   PubMed Web of Science ®Google Scholar
• Yao C, Su L, Shan J, et al. IGF/STAT3/NANOG/Slug signaling axis simultaneously controls epithelial-mesenchymal transition and stemness maintenance in colorectal cancer. Stem Cells. 2016;34:820–831. doi:10.1002/stem.232026840943
   PubMed Web of Science ®Google Scholar
• Vaquero J, Lobe C, Tahraoui S, et al. The IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma. Clin Cancer Res. 2018;24:4282–4296. doi:10.1158/1078-0432.CCR-17-372529716918
   PubMed Web of Science ®Google Scholar
• Megison ML, Gillory LA, Beierle EA. Cell survival signaling in neuroblastoma. Anticancer Agents Med Chem. 2013;13:563–575. 22934706
   PubMed Web of Science ®Google Scholar
• Chai H, Luo AZ, Weerasinghe P, Brown RE. Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line. Int J Clin Exp Pathol. 2010;3:408–415. 20490331
   PubMed Web of Science ®Google Scholar
• Galoczova M, Coates P, Vojtesek B. STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett. 2018;23:12. doi:10.1186/s11658-018-0078-029588647
   PubMed Web of Science ®Google Scholar
• Subramani R, Lopez-Valdez R, Arumugam A, Nandy S, Boopalan T, Lakshmanaswamy R. Targeting insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis. PLoS One. 2014;9:e97016. doi:10.1371/journal.pone.009701624809702
   PubMed Web of Science ®Google Scholar
• Wu K, Chang Q, Lu Y, et al. Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells. Oncotarget. 2013;4:2430–2438. doi:10.18632/oncotarget.143124280348
   PubMedGoogle Scholar
• Liu X, Qiao B, Zhao T, Hu F, Lam AK, Tao Q. Sox2 promotes tumor aggressiveness and epithelialmesenchymal transition in tongue squamous cell carcinoma. Int J Mol Med. 2018;42:1418–1426. doi:10.3892/ijmm.2018.374229956740
   PubMed Web of Science ®Google Scholar
• Pan Q, Meng L, Ye J, et al. Transcriptional repression of miR-200 family members by Nanog in colon cancer cells induces epithelial-mesenchymal transition (EMT). Cancer Lett. 2017;392:26–38. doi:10.1016/j.canlet.2017.01.03928163188
   PubMed Web of Science ®Google Scholar
• Song X, Wang J, Zheng T, et al. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. Mol Cancer. 2013;12:114. doi:10.1186/1476-4598-12-11424093956
   PubMed Web of Science ®Google Scholar
• Yu M, Xue H, Wang Y, et al. miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma. Int J Oncol. 2017;50:975–983. doi:10.3892/ijo.2017.385228098858
   PubMed Web of Science ®Google Scholar